Perrigo shareholders reject Mylan’s acquisition attempt
PITTSBURGH and DUBLIN — Mylan and Perrigo announced Friday in separate statements that fewer than 50.1% of Perrigo’s shareholders had tendered their shares to Mylan, ending a months-long acquisition effort by Mylan. When the deadline for shareholders — who had been approached directly by Mylan — passed at 8 a.m. EST on Friday, only 40% of shares had been tendered.
Mylan said that none of the shares tendered would be accepted and would be returned to shareholders, while Perrigo said it would immediately begin its $2 billion repurchase of shares — $5000 million worth of which it plans to complete by year’s end.
Mylan’s executive chairman Robert Coury, said that the acquisition was overall inessential to the company’s long-term strategy.
“As we have said all along, Mylan viewed Perrigo as a unique and exciting opportunity, but not one that was required for the future success of our company,” he said. “With one of the strongest balance sheets in our industry …. we are well-positioned to quickly execute on the next strategic, value-enhancing opportunities for our business, some of which we have already identified. a
Perrigo, for its part, expressed optimism about its future as an independent company, reiterating its long-held stance that Mylan’s $26 billion offer did not properly value the company.
“We have said all along that this offer from Mylan was a bad deal for our shareholders, as it significantly undervalued our durable business model and industry-leading future growth prospects,” Perrigo chairman and CEO Joseph Papa said. “Strong organic growth, a disciplined approach to M&A, and transparent, accessible corporate governance policies are the foundation of our successful business strategy. I am delighted that Perrigo shareholders voiced their clear support for this management team and our long-term strategy.”
LexisNexis folding Health Market Science into its brand family
ATLANTA — LexisNexis Risk Solutions, a provider of data, analytics and technology, on Thursday announced the brand transition of Health Market Science into the LexisNexis brand family.
The rebranding will begin in the fourth quarter of 2015 for the life sciences market, as well as other health care segments LexisNexis currently serves, to streamline branding efforts and reflect the organization’s commitment to combining its public records footprint, provider and claims data, analytics and big data technology.
“It’s a good time for our brand to reflect what LexisNexis brings to life sciences companies in terms of superior provider data knowledge, market intelligence and agile data management that helps our customers answer critical business questions resulting in operational effectiveness and efficiency,” said Theresa Greco, VP, Life Sciences, LexisNexis Risk Solutions.
LexisNexis health care solutions portfolio includes a provider referential database, which blends thousands of data sources, verification techniques and analytics. The company leverages proprietary linking algorithms and technology to match and build relationships across data sources and also delivers customized intelligence to meet the customer’s need.
Missing or outdated information about health care provider specialties and critical affiliations and organizational structures puts life sciences companies’ competitive advantages at risk. Armed with better health care practitioner information, they can move to account-based selling—targeting and reaching the right providers, at the right time, with the right information and in the right way. Life Sciences companies can also achieve compliance and commercial agility by leveraging the LexisNexis real-time data management and analytics solution, LexisNexis Agile Data Management.
“The acquisition of Health Market Science establishes LexisNexis as the health care authority on provider data and data management,” said Lee Rivas, CEO, Public Sector and Health Care, LexisNexis Risk Solutions. “Together, we deliver more accurate and comprehensive data-driven analytic solutions and services. This customer-centric approach, coupled with the experience of specialized health care data experts, enables transformation within the Life Sciences industry.”
Touro College of Pharmacy students organize ‘Operation Immunization’
Left to right: Touro College of Pharmacy students Rachel Jakobov; Tinnie Liao-Ng Yan; Christine Nguyen, and Angela Pantanawong
NEW YORK — Touro College of Pharmacy students provided vaccines to seniors this week as part of its third annual “Operation Immunization” as one of four events held in support of Flu Awareness Month and American Pharmacists Month, which included a flu clinic at TCOP, a lecture from a developer of the flu vaccine and a documentary on the 1918 Spanish Flu pandemic.
At “Operation Immunization” — which was organized by the college’s chapter of the American Pharmacists Association-Academy of Student Pharmacists — students screened seniors in East Harlem to ensure they could receive vaccines that were then administered by registered pharmacists.
“We are very committed to contributing our expertise in preventative medicine within the Harlem community and are proud of the contributions our students make to this significant public health initiative,” TCOP interim dean Dr. Zvi Loewy said.
Working with Rite Aid as a community partner, students organized the entirety of “Operation Immunization”, building on the pharmacists’ role in working to improve public health and gaining experience in patient interaction and meeting seniors’ needs.
"It's vitally important for seniors to receive vaccinations because adults over 65 years of age are more susceptible to the flu and also prone to other preventable diseases as well,” event organizer Christine Nguyen said. “As student pharmacists, it was our goal to administer as many immunizations as possible in order to do our part in protecting our senior population.”
Loading Post Please Wait...